HRTX (Heron Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings
Heron Therapeutics, Inc. (HRTX) is a publicly traded Healthcare sector company. As of May 21, 2026, HRTX trades at $0.89 with a market cap of $162.67M and a P/E ratio of -5.01. HRTX moved +0.18% today. Year to date, HRTX is -31.85%; over the trailing twelve months it is -55.98%. Its 52-week range spans $0.74 to $2.68. Analyst consensus is buy with an average price target of $3.50. Rallies surfaces HRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns HRTX stock?
Hedge funds tracked by Rallies that own HRTX include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Heron Therapeutics, Inc..
HRTX Key Metrics
Key financial metrics for HRTX
Metric
Value
Price
$0.89
Market Cap
$162.67M
P/E Ratio
-5.01
EPS
$-0.17
Dividend Yield
0.00%
52-Week High
$2.68
52-Week Low
$0.74
Volume
28
Avg Volume
0
Revenue (TTM)
$150.71M
Net Income
$-30.94M
Gross Margin
71.12%
Top Hedge Funds Holding HRTX
Orbimed Advisors holds 9.82M shares of HRTX, changed +50.73% as of Mar 31, 2026.
Panagora Asset holds 962.50K shares of HRTX, changed +118.63% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own HRTX include Orbimed Advisors and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Heron Therapeutics, Inc..
Does Rallies show 13F holders for HRTX?
Yes. Rallies tracks hedge fund and 13F ownership data for HRTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HRTX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for HRTX. It does not provide personalized investment advice.
